MEMBER'S LOGINX
| Invalid Username / Password | ||||||||
| Invalid Captcha | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- Compare Company
- International - pharmaceuticals
- SUVEN PHARMACEUTICALS - ADCOCK INGRAM (S. Africa)
SUVEN PHARMACEUTICALS vs ADCOCK INGRAM (S. Africa) - Comparison Results
ADCOCK INGRAM (S. Africa)
Adcock Ingram is a leading South African pharmaceutical manufacturer, marketer and distributor. The company occupies 10% share of the private pharmaceutical market in South Africa with a strong presence in over-the-counter (OTC) brands. Adcock is als... More
Financials
 SUVEN PHARMACEUTICALS  ADCOCK INGRAM |
| EQUITY SHARE DATA | |||||
|---|---|---|---|---|---|
| SUVEN PHARMACEUTICALS Mar-23 |
ADCOCK INGRAM Jun-14 |
SUVEN PHARMACEUTICALS/ ADCOCK INGRAM |
5-Yr Chart Click to enlarge
|
||
| High | Rs | 629 | 325 | - | |
| Low | Rs | 388 | 234 | - | |
| Sales per share (Unadj.) | Rs | 52.7 | 96.6 | - | |
| Earnings per share (Unadj.) | Rs | 16.2 | -24.3 | - | |
| Cash flow per share (Unadj.) | Rs | 18.0 | -20.2 | - | |
| Dividends per share (Unadj.) | Rs | 6.00 | 0 | - | |
| Avg Dividend yield | % | 1.2 | 0 | - | |
| Book value per share (Unadj.) | Rs | 68.2 | 75.8 | - | |
| Shares outstanding (eoy) | m | 254.57 | 168.78 | - | |
| Bonus / Rights / Conversions | 0 | 0 | - | ||
| Price / Sales ratio | x | 9.7 | 2.9 | 333.7% | |
| Avg P/E ratio | x | 31.5 | -11.5 | -274.0% | |
| P/CF ratio (eoy) | x | 28.2 | -13.9 | -203.4% | |
| Price / Book Value ratio | x | 7.5 | 3.7 | 202.3% | |
| Dividend payout | % | 37.1 | 0 | - | |
| Avg Mkt Cap | Rs m | 129,395 | 47,183 | 274.2% | |
| No. of employees | `000 | NA | 4.3 | 0.0% | |
| Total wages/salary | Rs m | 1,105 | 2,961 | 37.3% | |
| Avg. sales/employee | Rs Th | 0 | 3,798.6 | - | |
| Avg. wages/employee | Rs Th | 0 | 689.8 | - | |
| Avg. net profit/employee | Rs Th | 0 | -957.2 | - | |
| INCOME DATA | |||||
|---|---|---|---|---|---|
| Net Sales | Rs m | 13,403 | 16,307 | 82.2% | |
| Other income | Rs m | 464 | 114 | 406.0% | |
| Total revenues | Rs m | 13,867 | 16,421 | 84.4% | |
| Gross profit | Rs m | 5,739 | -2,826 | -203.1% | |
| Depreciation | Rs m | 477 | 704 | 67.8% | |
| Interest | Rs m | 128 | 442 | 29.0% | |
| Profit before tax | Rs m | 5,597 | -3,857 | -145.1% | |
| Minority Interest | Rs m | 0 | -11 | -0.0% | |
| Prior Period Items | Rs m | 0 | 0 | - | |
| Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
| Tax | Rs m | 1,484 | 241 | 615.9% | |
| Profit after tax | Rs m | 4,113 | -4,109 | -100.1% | |
| Gross profit margin | % | 42.8 | -17.3 | -247.1% | |
| Effective tax rate | % | 26.5 | -6.2 | -424.4% | |
| Net profit margin | % | 30.7 | -25.2 | -121.8% | |
| BALANCE SHEET DATA | |||||
|---|---|---|---|---|---|
| Current assets | Rs m | 11,554 | 11,944 | 96.7% | |
| Current liabilities | Rs m | 3,031 | 6,720 | 45.1% | |
| Net working cap to sales | % | 63.6 | 32.0 | 198.5% | |
| Current ratio | x | 3.8 | 1.8 | 214.5% | |
| Inventory Days | Days | 148 | 111 | 133.9% | |
| Debtors Days | Days | 302 | 124 | 243.8% | |
| Net fixed assets | Rs m | 9,547 | 6,962 | 137.1% | |
| Share capital | Rs m | 255 | 76 | 336.2% | |
| Net worth | Rs m | 17,352 | 12,799 | 135.6% | |
| Long term debt | Rs m | 46 | 4,498 | 1.0% | |
| Total assets | Rs m | 21,101 | 24,179 | 87.3% | |
| Interest coverage | x | 44.7 | -7.7 | -578.0% | |
| Debt to equity ratio | x | 0 | 0.4 | 0.7% | |
| Sales to assets ratio | x | 0.6 | 0.7 | 94.2% | |
| Return on assets | % | 20.1 | -15.2 | -132.5% | |
| Return on equity | % | 23.7 | -32.1 | -73.8% | |
| Return on capital | % | 32.9 | -19.8 | -166.1% | |
| CASH FLOW | |||||
|---|---|---|---|---|---|
| From Operations | Rs m | 4,509 | 1,392 | 323.9% | |
| From Investments | Rs m | -1,948 | -427 | 455.9% | |
| From Financial Activity | Rs m | -2,358 | 4,082 | -57.8% | |
| Net Cashflow | Rs m | 202 | 5,047 | 4.0% | |
The reporting currency for ADCOCK INGRAM (S. Africa) is South Africa Rand. All data has been converted at 4.48 Rs / ZAR
Compare SUVEN PHARMACEUTICALS With: ACTAVIS (US) MYLAN (US) TEVA PHARMA (Israel)
Compare SUVEN PHARMACEUTICALS With: MERCURY LAB. GSK PHARMA CHANDRA BHAGAT PHARMA KILITCH DRUGS PIRAMAL PHARMA
Today's Market
![Sensex Today Ends 189 Points Lower | IT Stocks Drag | REC Rallies 10%, Hitachi Energy 9%]()
Sensex Today Ends 189 Points Lower | IT Stocks Drag | REC Rallies 10%, Hitachi Energy 9%(Closing)
After opening the day on positive note, Indian share markets reversed the trend as the session progressed and ended lower.
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
- Multibagger Penny Stocks
- Basics of Value Investing
- Benjamin Graham
- How to Invest in Gold
- How to Invest in Silver
- Best Stocks to Buy Today
- Best Small-cap Stocks to Buy
- Best Bluechip Stocks to Buy
- Guide to Penny Stocks
- How to Invest in the Share Market
- Warren Buffett - The Value Investor
- Pick the Best Multibagger Stocks
TRENDING TOPICS
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.
103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407
Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com
LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.